Healthcare
21 articles on Healthcare, written by Shotlee and medically reviewed for clinical accuracy.
Should You Invest in Novo Nordisk, the Ozempic Manufacturer, in 2026?
Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.
2 min read
Semaglutide to Potentially Boost Ajanta Pharma's Growth Trajectory | Stock Market Update
Ajanta Pharma's recent agreement to market semaglutide across emerging markets has the potential to influence its medium-term growth. The company's established presence and strategic focus on branded generics contribute to a positive outlook. Financial analysts predict substantial revenue increases in the coming years.
3 min read
Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic
Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.
1 min read
Eli Lilly's Trajectory: Projecting 10 Years Ahead
Eli Lilly is currently thriving, fueled by the success of its GLP-1 drugs. However, factors such as market competition and the eventual expiration of patent protections pose potential challenges to its long-term growth.
3 min read
Year in Review 2025: From Ozempic to Yeztugo; Significant New Drug Approvals and Their Importance
2025 saw the approval of several groundbreaking medications, transforming the management of chronic diseases and preventive care. These advancements offer new hope for patients and clinicians alike, addressing critical needs in various medical fields.
3 min read
Shannonside Region: State Invests Nearly €2.63 Million on Ozempic | Shannonside.ie
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
1 min read
Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
1 min read
Delhi HC Rejects Stay on Order Permitting Dr. Reddy's Semaglutide Export
The Delhi High Court has upheld a previous ruling that allows Dr. Reddy's Laboratories to manufacture Semaglutide for export. This decision comes amid an ongoing patent dispute with Novo Nordisk, who claims Dr. Reddy's infringed on their Semaglutide patent.
3 min read
Mounjaro by Eli Lilly Included in China's National Health Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be added to China's state health insurance on January 1st. This inclusion could intensify competition among pharmaceutical companies. The move aims to improve access for China's large population.
1 min read
Ozempic, a Diabetes Medication, Slated for India Launch This Month
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
1 min read
Eli Lilly Reduces Zepbound Prices Amidst Weight Loss Medication Competition
Eli Lilly has announced price cuts for its weight loss medication Zepbound, aiming to improve accessibility for patients. The company is also seeking to increase the use of its digital healthcare platform, LillyDirect, through these changes.
3 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Mounjaro Delivered: UAE App Introduces Weight-Loss Medication Delivery
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
4 min read
Chinese Pharmaceutical Sector on the Verge of Global Expansion
China's pharmaceutical industry is rapidly ascending on the global stage, fueled by innovation and strategic alliances with Western companies. This rise presents both opportunities and challenges as China aims to become a major player in drug discovery and development.
7 min read
Weight Loss Medications Trigger 'Major Impact' on Tailoring, Says Savile Row Executive
A Savile Row executive reports that the increasing use of weight loss medications is causing substantial changes in the tailoring business. Rapid weight loss among customers necessitates significant alterations or complete remakes of suits. This trend is particularly noticeable among male clients in their 40s and 50s.
2 min read
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
2 min read
The Heated Race to Dominate the Booming GLP-1 Medication Arena
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
3 min read
Obesity Crisis in America Meets Ozempic Boom: Data Shows GLP-1 Hotspots
A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.
3 min read
Novo Nordisk Stock: Factors Contributing to This Week's Decline | The Motley Fool
Shares of Novo Nordisk have decreased substantially. This drop is influenced by increased competition in the GLP-1 market and a revised outlook for future growth. The global drugmaker faces headwinds from competitors like Eli Lilly.
2 min read
Pfizer Clinches $10B Acquisition of Obesity Drug Firm Metsera After Bidding War
Pfizer has successfully acquired Metsera, a company specializing in obesity drug development, for $10 billion, prevailing over Novo Nordisk in a competitive bidding process. This acquisition marks Pfizer's entry into the expanding obesity drug market. Metsera's treatments are still several years from regulatory approval.
3 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read